Concerns Arise Over New Alzheimer's Treatments

Recent research from Cambridge University has raised concerns about the effectiveness and safety of two new Alzheimer’s treatments, lecanemab and donanemab. These drugs, which have recently entered the market, are intended to address the growing need for effective Alzheimer’s therapies as the global population ages. However, the study highlights troubling side effects, minimal proven benefits, and challenges in administering these medications to patients. Alzheimer’s disease, the most prevalent form of dementia, affects approximately 55 million people worldwide, with the World Health Organization noting that it accounts for up to 70 percent of dementia cases. In a Phase 3 trial for donanemab, developed by Eli Lilly, participants experienced a 22 to 29 percent reduction in cognitive decline over 76 weeks compared to a placebo. Despite these findings, the latest analysis published in *Alzheimer's & Dementia* indicates that the actual benefits are small and fall short of established clinical significance. The researchers also expressed concern over the frequency and severity of side effects associated with both drugs. Lead author Sebastian Walsh emphasized that only a limited number of Alzheimer’s patients would qualify for treatment, suggesting a need for healthcare systems to adapt to new models that prioritize early diagnosis and intervention. The approval of these drugs has sparked debate among regulators. Co-author Edo Richard noted that, despite the concerns, some patients with early-stage Alzheimer’s may still seek these treatments due to the desperation associated with the disease.